ASLAN Pharmaceuticals Limited

3.01+0.0200+0.67%Vol 1.33M1Y Perf 81.50%
Apr 22nd, 2021 16:00 DELAYED
BID3.00 ASK3.04
Open3.00 Previous Close2.99
Pre-Market- After-Market-
 - -%  - -
Target Price
8.50 
Analyst Rating
Strong Buy 1.00
Potential %
182.39 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     40.28
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap114.35M 
Earnings Rating
Neutral
Price Range Ratio 52W %
31.88 
Earnings Date
10th May 2021

Today's Price Range

2.953.27

52W Range

1.266.75

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
0.00%
1 Month
-22.02%
3 Months
38.71%
6 Months
63.59%
1 Year
81.50%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ASLN3.010.02000.67
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Mngmt EffectivenessValueIndustryS&P 500US Markets
ROE (5Y Avg)
-261.98
ROE last 12 Months
-3 712.77
ROA (5Y Avg)
-129.42
ROA last 12 Months
-165.77
ROC (5Y Avg)
-111.69
ROC last 12 Months
-221.98
Return on invested Capital Q
-130.87
Return on invested Capital Y
-150.87
Assets Turnover
0.00
Receivables Turnover
0.00
Financial StrengthValueIndustryS&P 500US Markets
1.90
2.00
0.47
0.91
-32.40
Leverage Ratio -1.40
ProfitabilityValueIndustryS&P 500US Markets
0.00
-168.60
-156.60
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.10-0.0280.00
Q02 2020-0.10-0.100.00
Q01 2020-0.11-0.0827.27
Q04 2019-0.15-0.20-33.33
Q03 2019-0.22-0.0386.36
Q02 2019-0.20-0.25-25.00
Q01 2019-0.22-0.1531.82
Q04 2018-0.37-0.355.41
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.400.00-
3/2021 QR-0.1121.43Positive
6/2021 QR-0.0846.67Positive
12/2021 FY-0.3833.33Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.11
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.33M
Shares Outstanding37.99M
Trades Count3.93K
Dollar Volume58.88M
Avg. Volume1.95M
Avg. Weekly Volume687.74K
Avg. Monthly Volume626.42K
Avg. Quarterly Volume2.32M

ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) stock closed at 3.01 per share at the end of the most recent trading day (a 0.67% change compared to the prior day closing price) with a volume of 1.33M shares and market capitalization of 114.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. ASLAN Pharmaceuticals Limited CEO is Carl Firth.

The one-year performance of ASLAN Pharmaceuticals Limited stock is 81.5%, while year-to-date (YTD) performance is 64.48%. ASLN stock has a five-year performance of %. Its 52-week range is between 1.26 and 6.75, which gives ASLN stock a 52-week price range ratio of 31.88%

ASLAN Pharmaceuticals Limited currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 5.18, a price-to-sale (PS) ratio of 23.43, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -165.77%, a ROC of -221.98% and a ROE of -3 712.77%. The company’s profit margin is -%, its EBITDA margin is -156.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ASLAN Pharmaceuticals Limited, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. ASLAN Pharmaceuticals Limited’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for ASLAN Pharmaceuticals Limited is Strong Buy (1), with a target price of $8.5, which is +182.39% compared to the current price. The earnings rating for ASLAN Pharmaceuticals Limited stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ASLAN Pharmaceuticals Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ASLAN Pharmaceuticals Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 45.65, ATR14 : 0.44, CCI20 : -62.38, Chaikin Money Flow : -0.16, MACD : -0.09, Money Flow Index : 48.13, ROC : -15.69, RSI : 48.47, STOCH (14,3) : 23.08, STOCH RSI : 0.65, UO : 44.04, Williams %R : -76.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ASLAN Pharmaceuticals Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Moderate Buy
1.67
Moderate Buy
1.67

ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology and oncology-focused biopharmaceutical company. It is engaged in developing treatments to transform the lives of patients. The company has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.

CEO: Carl Firth

Telephone: +65 62224235

Address: 83 Clemenceau Avenue, Singapore 239920, , SG

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

51%49%

Bearish Bullish

59%41%

News

Stocktwits